Joseph A Miccio1, Andrew Barsky2, Sarah Gao1, Vivek Verma3, Sonal S Noticewala4, Vikram Jairam1, Skyler B Johnson5, James B Yu1, James E Hansen1, Sanjay Aneja1,6, Yi An1, Roy H Decker1, S Bulent Omay7, Jing Li4, Goldie A Kurtz2, Michelle Alonso-Basanta2, John Y K Lee7, Veronica L Chiang8, Henry S Park1. 1. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06511, USA. 2. Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 3. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA. 4. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, TX 77030, USA. 5. Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. 6. Center for Outcomes Research and Evaluation (CORE) Yale School of Medicine, New Haven, CT 06511, USA. 7. Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 8. Department of Neurosurgery, Yale School of Medicine, New Haven, CT, 06511, USA.
Abstract
Introduction: Patients with small cell lung cancer (SCLC) brain metastasis (BM) typically receive whole brain radiotherapy (WBRT) as data regarding upfront radiosurgery (SRS) in this setting are sparse. Methods: Patients receiving SRS for SCLC BM without prior brain radiation were identified at three U.S. institutions. Overall survival (OS), freedom from intracranial progression (FFIP), freedom from WBRT (FFWBRT), and freedom from neurologic death (FFND) were determined from time of SRS. Results: Thirty-three patients were included with a median of 2 BM (IQR 1-6). Median OS and FFIP were 6.7 and 5.8 months, respectively. Median FFIP for patients with ≤2 versus >2 BM was 7.1 versus 3.6 months, p=0.0303. Eight patients received salvage WBRT and the 6-month FFWBRT and FFND were 87.8%. and 90.1%, respectively. Conclusions: Most SCLC patients with BM who received upfront SRS avoided WBRT and neurologic death, suggesting that SRS may be an option in select patients.
Introduction: Patients with small cell lung cancer (SCLC) brain metastasis (BM) typically receive whole brain radiotherapy (WBRT) as data regarding upfront radiosurgery (SRS) in this setting are sparse. Methods:Patients receiving SRS for SCLC BM without prior brain radiation were identified at three U.S. institutions. Overall survival (OS), freedom from intracranial progression (FFIP), freedom from WBRT (FFWBRT), and freedom from neurologic death (FFND) were determined from time of SRS. Results: Thirty-three patients were included with a median of 2 BM (IQR 1-6). Median OS and FFIP were 6.7 and 5.8 months, respectively. Median FFIP for patients with ≤2 versus >2 BM was 7.1 versus 3.6 months, p=0.0303. Eight patients received salvage WBRT and the 6-month FFWBRT and FFND were 87.8%. and 90.1%, respectively. Conclusions: Most SCLCpatients with BM who received upfront SRS avoided WBRT and neurologic death, suggesting that SRS may be an option in select patients.
Authors: Rodney E Wegner; Adam C Olson; Douglas Kondziolka; Ajay Niranjan; L Dade Lundsford; John C Flickinger Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-23 Impact factor: 7.038
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Benjamin H Kann; Henry S Park; Skyler B Johnson; Veronica L Chiang; James B Yu Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316